| CHANAN-KHAN, Asher, Paula CRAMER, Fatih DEMIRKAN, Graeme FRASER, Rodrigo Santucci SILVA, Sebastian GROSICKI, Aleksander PRISTUPA, Ann JANSSENS, Jiří MAYER, Nancy L BARTLETT, Marie-Sarah DILHUYDY, Halyna PYLYPENKO, Javier LOSCERTALES, Abraham AVIGDOR, Simon RULE, Diego VILLA, Olga SAMOILOVA, Panagiots PANAGIOTIDIS, Andre GOY, Anthony MATO, Miguel A PAVLOVSKY, Claes KARLSSON, Michelle MAHLER, Mariya SALMAN, Steven SUN, Charles PHELPS, Sriram BALASUBRAMANIAN, Angela HOWES a Michael HALLEK. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncology. New York: Elsevier Science INC, 2016, roč. 17, č. 2, s. 200-211. ISSN 1470-2045. Dostupné z: https://dx.doi.org/10.1016/S1470-2045(15)00465-9. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1322545,
author = {ChananandKhan, Asher and Cramer, Paula and Demirkan, Fatih and Fraser, Graeme and Silva, Rodrigo Santucci and Grosicki, Sebastian and Pristupa, Aleksander and Janssens, Ann and Mayer, Jiří and Bartlett, Nancy L and Dilhuydy, MarieandSarah and Pylypenko, Halyna and Loscertales, Javier and Avigdor, Abraham and Rule, Simon and Villa, Diego and Samoilova, Olga and Panagiotidis, Panagiots and Goy, Andre and Mato, Anthony and Pavlovsky, Miguel A and Karlsson, Claes and Mahler, Michelle and Salman, Mariya and Sun, Steven and Phelps, Charles and Balasubramanian, Sriram and Howes, Angela and Hallek, Michael},
article_location = {New York},
article_number = {2},
doi = {http://dx.doi.org/10.1016/S1470-2045(15)00465-9},
keywords = {BRUTON TYROSINE KINASE; MANTLE CELL LYMPHOMA; INHIBITOR IBRUTINIB; PCI-32765; BTK; CYCLOPHOSPHAMIDE; FLUDARABINE; MALIGNANCY; DISEASE; TRIAL},
language = {eng},
issn = {1470-2045},
journal = {Lancet Oncology},
title = {Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study},
volume = {17},
year = {2016}
}
TY - JOUR
ID - 1322545
AU - Chanan-Khan, Asher - Cramer, Paula - Demirkan, Fatih - Fraser, Graeme - Silva, Rodrigo Santucci - Grosicki, Sebastian - Pristupa, Aleksander - Janssens, Ann - Mayer, Jiří - Bartlett, Nancy L - Dilhuydy, Marie-Sarah - Pylypenko, Halyna - Loscertales, Javier - Avigdor, Abraham - Rule, Simon - Villa, Diego - Samoilova, Olga - Panagiotidis, Panagiots - Goy, Andre - Mato, Anthony - Pavlovsky, Miguel A - Karlsson, Claes - Mahler, Michelle - Salman, Mariya - Sun, Steven - Phelps, Charles - Balasubramanian, Sriram - Howes, Angela - Hallek, Michael
PY - 2016
TI - Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
JF - Lancet Oncology
VL - 17
IS - 2
SP - 200-211
EP - 200-211
PB - Elsevier Science INC
SN - 14702045
KW - BRUTON TYROSINE KINASE
KW - MANTLE CELL LYMPHOMA
KW - INHIBITOR IBRUTINIB
KW - PCI-32765
KW - BTK
KW - CYCLOPHOSPHAMIDE
KW - FLUDARABINE
KW - MALIGNANCY
KW - DISEASE
KW - TRIAL
N2 - Background Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or refractory setting. We assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma. Interpretation In patients eligible for bendamustine plus rituximab, the addition of ibrutinib to this regimen results in significant improvements in outcome with no new safety signals identified from the combination and a manageable safety profile.
ER -
CHANAN-KHAN, Asher, Paula CRAMER, Fatih DEMIRKAN, Graeme FRASER, Rodrigo Santucci SILVA, Sebastian GROSICKI, Aleksander PRISTUPA, Ann JANSSENS, Jiří MAYER, Nancy L BARTLETT, Marie-Sarah DILHUYDY, Halyna PYLYPENKO, Javier LOSCERTALES, Abraham AVIGDOR, Simon RULE, Diego VILLA, Olga SAMOILOVA, Panagiots PANAGIOTIDIS, Andre GOY, Anthony MATO, Miguel A PAVLOVSKY, Claes KARLSSON, Michelle MAHLER, Mariya SALMAN, Steven SUN, Charles PHELPS, Sriram BALASUBRAMANIAN, Angela HOWES a Michael HALLEK. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. \textit{Lancet Oncology}. New York: Elsevier Science INC, 2016, roč.~17, č.~2, s.~200-211. ISSN~1470-2045. Dostupné z: https://dx.doi.org/10.1016/S1470-2045(15)00465-9.
|
